Navigation Links
Codexis Appoints Interim Chief Executive Officer
Date:2/17/2012

REDWOOD CITY, Calif., Feb. 17, 2012 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that effective immediately, the Board of Directors has appointed Peter Strumph as the company's interim Chief Executive Officer.  Alan Shaw, Ph.D. has resigned as President and Chief Executive Officer and from the Board of Directors to pursue other interests.  He will continue to serve as a special advisor to the Board of Directors.  The Board of Directors has appointed a special committee that will oversee the CEO search and transition.  Heidrick & Struggles has been retained for a worldwide search, which will include both internal and external candidates.

"We are grateful to Alan for his many years of service in leading Codexis from its inception and are pleased that he has agreed to serve as a special advisor to the Board," said Thomas Baruch, Chairman of the Board for Codexis, Inc.  "We are confident that Peter's executive leadership experience and deep understanding of the business will ensure a smooth transition during our search for a permanent CEO."

"Codexis has a tremendous leadership team in place, and I am pleased to continue supporting the company as it works to commercialize industrial enzymes in the biofuel, chemical and pharmaceutical industries," said Dr. Shaw.

Mr. Strumph was the Senior Vice President and Business Head of Pharmaceuticals, where he oversaw a 49% annual increase in pharmaceutical product sales in 2011, as well as the Senior Vice President of Commercial Operations since joining Codexis in 2010.  Mr. Strumph has more than twenty years experience in senior manufacturing and operations management in the biopharmaceutical industry, including executive leadership positions for ten years at CV Therapeutics where he managed their operational, development and commercial activities.  He is a former Naval officer, and holds an MBA from the University of Pennsylvania's Wharton School of Business.   

About Codexis, Inc.

Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals and pharmaceutical intermediates.  Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol.  Partners and customers include global leaders such as Shell, Merck and Pfizer.  For more information, see www.codexis.com.

 

Contacts:
Investors: Jay Sarwar, ir@codexis.com, 650-421-8126
Media: Wes Bolsen, media@codexis.com, 650-421-8100


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Announces CFO Departure
2. Codexis to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on February 7, 2012
3. Codexis Reports Third Quarter 2011 Results
4. 50 Pharma Companies Worldwide Now Use Codexis In Process Development
5. Codexis Names Veteran Chemical Executive to Lead Codexis do Brasil
6. Codexis, Raizen to Develop First Generation Ethanol
7. Codexis to Present at Three Investor Conferences in September
8. Codexis Presents Carbon Capture Update at DoE/NETL Conference
9. Codexis Board Elects Pedro I. Mizutani, Raizen EVP, as Director
10. Codexis Reports Second Quarter 2011 Results
11. Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance ... greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to ... and deadly chromosome abnormality. , After struggling since birth with several health challenges, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... a national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel ... also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
Breaking Medicine News(10 mins):